Home/ Stocks/ CRSP

CRISPR Therapeutics AG

CRSP XNAS

$53.46 -0.46 (-0.86%) ▼ 15-min delayed

Open

N/A

High

N/A

Low

N/A

Volume

N/A

Market Cap

$5.13B

About CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 393 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$3.51M	$-581,599,000	$-6.47
FY 2025	$3.51M	$-581,599,000	$-6.47
Q3 2025	$889.0K	$-106,441,000	$-1.17
Q2 2025	$892.0K	$-208,549,000	$-2.40

Ticker Daily Articles on CRSP

How to Trade Options Around Earnings (Without Getting Crushed)

Alex Chen · 7h ago · News

Get CRSP Alerts

Stay ahead with breaking news, price alerts, and expert analysis on CRISPR Therapeutics AG.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.